4A5 Stock Overview
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Fagron NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €18.18 |
| 52 Week High | €19.26 |
| 52 Week Low | €16.52 |
| Beta | 0.26 |
| 11 Month Change | -2.78% |
| 3 Month Change | -3.71% |
| 1 Year Change | 6.13% |
| 33 Year Change | 37.21% |
| 5 Year Change | -1.41% |
| Change since IPO | 82.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4A5 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -2.7% | -0.3% | -0.4% |
| 1Y | 6.1% | 14.5% | 7.1% |
Return vs Industry: 4A5 underperformed the German Healthcare industry which returned 14.5% over the past year.
Return vs Market: 4A5 matched the German Market which returned 7.1% over the past year.
Price Volatility
| 4A5 volatility | |
|---|---|
| 4A5 Average Weekly Movement | 2.0% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4A5 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4A5's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,647 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.
Fagron NV Fundamentals Summary
| 4A5 fundamental statistics | |
|---|---|
| Market cap | €1.33b |
| Earnings (TTM) | €77.94m |
| Revenue (TTM) | €820.76m |
17.1x
P/E Ratio1.6x
P/S RatioIs 4A5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4A5 income statement (TTM) | |
|---|---|
| Revenue | €820.76m |
| Cost of Revenue | €458.22m |
| Gross Profit | €362.54m |
| Other Expenses | €284.61m |
| Earnings | €77.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.07 |
| Gross Margin | 44.17% |
| Net Profit Margin | 9.50% |
| Debt/Equity Ratio | 69.2% |
How did 4A5 perform over the long term?
See historical performance and comparison